Insider Transactions in Q3 2019 at Fulcrum Therapeutics, Inc. (FULC)
Insider Transaction List (Q3 2019)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 22
2019
|
Glaxosmithkline PLC |
BUY
Conversion of derivative security
|
Indirect |
1,785,714
+50.0%
|
-
|
|
Jul 22
2019
|
Sanofi > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
93,750
+14.38%
|
$1,500,000
$16.0 P/Share
|
|
Jul 22
2019
|
Sanofi > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
464,285
+50.0%
|
-
|
|
Jul 22
2019
|
Casdin Capital, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
140,000
+6.65%
|
$2,100,000
$15.0 P/Share
|
|
Jul 22
2019
|
Casdin Capital, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
464,285
+50.0%
|
-
|
|
Jul 22
2019
|
Third Rock Ventures Iv, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
81,250
+3.35%
|
$1,300,000
$16.0 P/Share
|
|
Jul 22
2019
|
Third Rock Ventures Iv, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,261,904
+50.0%
|
-
|
|
Jul 22
2019
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
81,250
+1.34%
|
$1,300,000
$16.0 P/Share
|
|
Jul 22
2019
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
5,595,238
+48.76%
|
-
|